Skip to main content
Fig. 6 | BMC Bioinformatics

Fig. 6

From: PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients

Fig. 6

PDXGEM prediction for response to Cetuximab in metastatic colorectal cancer patient. a Distribution of PDXGEM scores (y-axis) is compared between metastatic colorectal cancer patients with complete response (CR) or partial response (PR) and those with stable of disease (SD) or progressive disease (PD) after treatment with cetuximab. Blue and red dots are subjects with or without positive epidermal growth factor receptor (EGFR) expression, respectively. b PDXGEM scores stratified by KRAS mutation status. c Kaplan-Meier curves of overall survival in metastatic colorectal cancer patients who did not receive cetuximab

Back to article page